3Aviles A, Diaz-Maqueo J C, Talavera A, et al. Bone marrow protection with amifostine in the treatment of high-risk malignant lymphoma[J]. Eur J Cancer, 1997,33(8):1323-1325.
4Bergijk EC, Munaut C, Baelde JJ, et al. A histologic study of the extracellular matrix during the development of glomeruloscle- rosis in murine chronic graft-versus-host disease. Am J Pathol, 1992, 140: 1147-1156.
6Gesualdo L, Grandaliano G. Monocyte recruitment in cryogloba- linemie membrano proliferative glomerulonephritis: a pathogenet- ie role for monoeyte ehemotatic peptide-1 Kidney Intern, 1997, 51: 155-163.
7Hasegawa H, Kohno M, Sasaki M, et al. Antagonist of monocyte chemoattraetant protein-1 ameliorates the initiation and progres- sion of lupus nephritis and renal vasculitis in MRL/lpr mice. Arthritis Rheum, 2003, 48: 2555-2566.
8Zhao Z, Burkly LC, Campbell S. TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft- versus-host model of systemic lupus erythematosus. J Immunol, 2007, 179: 7949-7958.
9Schwartz N, Michaelson JS, Putterman C. Lipocalin-2, TWEAK, and other cytokines as urinary biomarkers for lupus nephritis. Ann N Y Acad Sci, 2007, 1109: 265-274.
10Tiara S, Li J, Wang L, et al. Urinary levels of RANTES and M- CSF are predictors of lupus nephritis flare. Inflamm Res, 2007, 56: 304-310.
